Methamphetamine Abuse
Conditions
Brief summary
This study will link findings from neuroscience with clinical outcomes using contingency management (CM) to identify changes in brain structure and function that emerge during purely behavioral therapy for methamphetamine (MA) use.
Detailed description
This study will correlate MA-abstinence outcomes from an 8-week program of voucher-based incentives using an escalating schedule for 30 treatment-seeking, MA-dependent individuals with scores on tasks of working memory and assessments of neuropsychological and demographic status. At the beginning and end of the CM program, participants will participate in MRI scans while performing a working memory task and will complete a battery of select neurocognitive and psychological assays to address two specific aims: (1) to determine whether changes in neural function within frontostriatal circuitry from baseline to end of the 8-week CM program are associated with parallel changes in measures of cognitive control and impulsivity and with MA abstinence outcomes and (2) to determine whether structural changes in frontostriatal circuitry over the 8-week CM intervention correspond with neurocognitive, psychological and MA abstinence measures.
Interventions
BEHAVIORALContingency Management
as described above
Sponsors
University of Cape Town
University of California, Los Angeles
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* provide voluntary informed consent * meet DSM-5 criteria for MA or amphetamine use disorder * provide at least one urine sample positive for MA/amphetamine metabolites during screening (i.e. prior to the commencement of the study). * aged 18-45 * right-handed * English-speaking
Exclusion criteria
* currently receiving treatment for stimulant addiction or needing more intensive treatment than outpatient care * meet DSM-5 criteria for substance use disorder other than nicotine * unable to attend 4+ visits during the 2-week screening period or to complete measures * Physical or mental illness that would require intervention that would alter imaging or that would interfere with safe study participation * pregnant, claustrophobic, or have metal prostheses, cardiac pacemakers, or metal clips that are incompatible with the scanner * HIV positive status * unable to comprehend written or spoken English * currently taking psychiatric medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| fMRI Measures | Change b/w baseline and 8 Weeks | measures of resting state connectivity |
| Responses to Contingency Management | 8 weeks | urine samples documenting methamphetamine abstinence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Stop Signal Task | Change b/w baseline and 8 Weeks | measure of inhibitory control |
| Continuous Performance Task | Change b/w baseline and 8 Weeks | test of sustained attention |
| Stroop | Change b/w baseline and 8 Weeks | test of inhibitory control |
| Balloon Analog Risk Task | Change b/w baseline and 8 Weeks | measure of risk taking and decision making |
Countries
South Africa
Outcome results
None listed